BRCA1 and posterior cortical atrophy: The PROfound phase III clinical study revealed that patients with PCa with homologous recombination repair (HRR) gene mutations can benefit from olaparib monotherapy; in particular, the risk of radiographic progression (66%) or death could be reduced in patients with BRCA1/2 and ATM mutations (7).